Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis
Interventions: Lutikizumab, Placebo, Ravagalimab, ABBV-8736, ABBV-701, ABBV-848, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 49
States / cities: Peoria, Arizona • Jonesboro, Arkansas • Beverly Hills, California + 42 more

Conditions: Psoriasis
Interventions: Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 32
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 29 more

Conditions: Arthritis, Juvenile Idiopathic
Interventions: Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more

Conditions: Hidradenitis Suppurativa
Interventions: PTM-001, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Redwood City, California • Worcester, Massachusetts • Cincinnati, Ohio

Conditions: Uveitis, JIA
Interventions: Adalimumab, Placebo; Biological · Other
Lead sponsor: Nisha Acharya; Other
Eligibility: 2 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Colitis, Ulcerative
Interventions: Vedolizumab, Adalimumab placebo, Adalimumab, Vedolizumab placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more

Conditions: Rheumatoid Arthritis
Interventions: adalimumab, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 48
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 44 more

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550, Placebo, Biologic TNFi; Drug · Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 38
States / cities: Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Adalimumab Biosimilars Injection, Placebo; Drug · Other
Lead sponsor: Daniel Moriarity; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: Bimekizumab, Adalimumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more

Conditions: Rhematoid Arthritis
Interventions: Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 60
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 30
States / cities: Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab, Placebo; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Psoriasis
Interventions: CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo; Drug
Lead sponsor: Janssen Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo, Adalimumab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Rancho Mirage, California • Duncansville, Pennsylvania

Conditions: Crohn's Disease
Interventions: Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 43
States / cities: Berkeley, California • Long Beach, California • San Diego, California + 36 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab; Drug · Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Interventions: Adalimumab Injection [Humira], Saline Solution for Injection; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Torrance, California

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Placebo, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Beverly Hills, California • Encino, California • Irvine, California + 6 more

Conditions: Psoriasis
Interventions: Placebo, Adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more

Conditions: Interstitial Cystitis
Interventions: Adalimumab, inactive drug; Drug · Other
Lead sponsor: ICStudy, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Escondido, California

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 9
States / cities: Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more

Conditions: Psoriasis
Interventions: adalimumab, MTX, placebo adalimumab, placebo MTX; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Arthritis, Rheumatoid
Interventions: Adalimumab, CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 22
States / cities: Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more

Search by objective public record fields.

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

Adalimumab in JIA-associated Uveitis Stopping Trial

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

Precision Depression Adalimumab Trial

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Remission in Subjects With Crohn's Disease, 1 Year Phase

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

Efficacy Study of Adalimumab to Treat Interstitial Cystitis

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis